Literature DB >> 17277428

Bone mineral density in beta-thalassemia major and intermedia.

Mehran Karimi1, Alireza Fotouhi Ghiam, Alireza Hashemi, Saied Alinejad, Mahmood Soweid, Sara Kashef.   

Abstract

OBJECTIVE: This study was conducted to assess bone mineral density (BMD) and bone mineral content (BMC) in patients with thalassemia major and intermedia, and to correlate them with biochemical and hematological profile.
DESIGN: 106 thalassemic patients (49 major and 57 intermedia) were scanned by dual energy xray absorptiometry technique for BMD and BMC at lumbar spine and femoral neck. The effects of sex, transfusion/chelation program as well as hemoglobin, calcium, phosphorus, alkaline phosphatase and serum ferritin level were also evaluated on BMD and BMC.
RESULTS: Patients with thalassemia major and intermedia, younger than 20 yr, showed lower BMD and BMC in the lumbar region (p < 0.05). Both parameters correlated significantly with hemoglobin level; other biochemical and hematological parameters did not influence BMD and BMC values.
CONCLUSION: Bone marrow density is a good index of bone status in patients with Thalassemia and should be done in these patients annually.

Entities:  

Mesh:

Year:  2007        PMID: 17277428

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  18 in total

1.  Bone disease in adult patients with β-thalassaemia major: a case-control study.

Authors:  Marina Baldini; Stella Forti; Alessandra Orsatti; Fabio Massimo Ulivieri; Lorena Airaghi; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Intern Emerg Med       Date:  2011-12-17       Impact factor: 3.397

2.  Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover.

Authors:  Ellen B Fung; Elliott P Vichinsky; Janet L Kwiatkowski; James Huang; Laura K Bachrach; Aenor J Sawyer; Babette S Zemel
Journal:  Bone       Date:  2011-04-05       Impact factor: 4.398

3.  Evaluation of osteopathy in thalassemia by bone mineral densitometry and biochemical indices.

Authors:  Rashid Merchant; Amish Udani; Vipla Puri; Valentina D'cruz; Deepak Patkar; Aarti Karkera
Journal:  Indian J Pediatr       Date:  2010-08-25       Impact factor: 1.967

4.  Endocrine and metabolic disorders in β-thalassemiamajor patients.

Authors:  Fatemeh Saffari; Abolfazl Mahyar; Shabnam Jalilolgadr
Journal:  Caspian J Intern Med       Date:  2012

Review 5.  Musculoskeletal imaging manifestations of beta-thalassemia.

Authors:  Maryam Hajimoradi; Sara Haseli; Alireza Abadi; Majid Chalian
Journal:  Skeletal Radiol       Date:  2021-02-09       Impact factor: 2.199

6.  Predictors of osteoclast activity in patients with sickle cell disease.

Authors:  Mehdi Nouraie; Kevin Cheng; Xiaomei Niu; Evadne Moore-King; Margaret F Fadojutimi-Akinsi; Caterina P Minniti; Craig Sable; Sohail Rana; Niti Dham; Andrew Campbell; Gregory Ensing; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

7.  Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice.

Authors:  Richard Coffey; Grace Jung; Joseph D Olivera; Gabriel Karin; Renata C Pereira; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2022-01-20       Impact factor: 22.113

Review 8.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

9.  Bone Mineral Density and Hemoglobin Levels: Opposite Associations in Younger and Older Women.

Authors:  Tzyy-Ling Chuang; Malcolm Koo; Mei-Hua Chuang; Yuh-Feng Wang
Journal:  Int J Environ Res Public Health       Date:  2021-05-20       Impact factor: 3.390

10.  Clinical development of neridronate: potential for new applications.

Authors:  Davide Gatti; Maurizio Rossini; Ombretta Viapiana; Luca Idolazzi; Silvano Adami
Journal:  Ther Clin Risk Manag       Date:  2013-04-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.